Table 2. Univariate analysis of prognostic factors for NPC patients.

Outcomes	Variable	B	p	HR	95%CI for HR
OS
	Sex (male vs. female)	-0.197	0.640	0.821	0.359–1.876
	Age (>44 vs. ≤44)	-0.334	0.430	0.716	0.313–1.641
	Clinical stage (IV vs. II&III)	0.779	0.061	2.179	0.965–4.922
	T stage (T3-4 vs. T1-2)	-0.586	0.177	0.557	0.238–1.304
	N stage (N2-3 vs. N0-1)	1.725	0.002	5.614	1.915–16.457
	M stage (M1 vs. M0)	1.051	0.059	2.860	0.960–8.517
	PTOV1 expression (high vs. low)	1.499	0.003	4.475	1.668–12.010
PFS
	Sex (male vs. female)	-0.118	0.7	0.889	0.488–1.619
	Age (>44 vs. ≤44)	-0.269	0.37	0.764	0.425–1.376
	Clinical stage (IV vs. II&III)	0.059	0.843	1.061	0.592–1.902
	T stage (T3-4 vs. T1-2)	0.063	0.86	1.065	0.528–2.149
	N stage (N2-3 vs. N0-1)	0.206	0.488	1.229	0.686–2.203
	M stage (M1 vs. M0)	1.046	0.018	2.845	1.196–6.768
	PTOV1 expression (high vs. low)	1.102	0.001	3.010	1.551–5.841

Abbreviations: CI = confident interval; HR = hazard ratio; OS = overall survival; PFS = progression-free survival